Summary of COVID-19 efmarodocokin alfa studies

1. Waters et al., Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial

266 patient efmarodocokin alfa late treatment RCT: 15% higher mortality (p=0.67) and 13% improved recovery (p=0.35).
RCT 396 hospitalized patients with severe COVID-19 pneumonia showing no significant difference in time to recovery with astegolimab (IL-33 receptor blocker) or efmarodocokin alfa (IL-22 pathway activator). Median time to recovery was 11 days for astegolimab, 10 days for efmarodocokin alfa, and 10 days for placebo (p=0.93 and p=0.36 respectively). Neither drug showed benefit for secondary endpoints including mortality, hospital discharge time, ICU admission, or mechanical ventilation.
Nov 2022, Critical Care Medicine, https://journals.lww.com/10.1097/CCM.0000000000005716, https://c19p.org/waters2efm